492 related articles for article (PubMed ID: 23771907)
1. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
3. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
Cao J; Wang X; Dai T; Wu Y; Zhang M; Cao R; Zhang R; Wang G; Jiang R; Zhou BP; Shi J; Kang T
Theranostics; 2018; 8(10):2739-2751. PubMed ID: 29774072
[No Abstract] [Full Text] [Related]
4. The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells.
Lee KJ; Kim NH; Kim HS; Kim Y; Lee JJ; Kim JH; Cho HY; Jeong SY; Park ST
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241228
[No Abstract] [Full Text] [Related]
5. ROR2 promotes the epithelial-mesenchymal transition by regulating MAPK/p38 signaling pathway in breast cancer.
Xu J; Shi J; Tang W; Jiang P; Guo M; Zhang B; Ma G
J Cell Biochem; 2020 Oct; 121(10):4142-4153. PubMed ID: 32048761
[TBL] [Abstract][Full Text] [Related]
6. miR‑30a inhibits epithelial‑mesenchymal transition and metastasis in triple‑negative breast cancer by targeting ROR1.
Wang X; Qiu H; Tang R; Song H; Pan H; Feng Z; Chen L
Oncol Rep; 2018 Jun; 39(6):2635-2643. PubMed ID: 29693179
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.
Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG
Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057
[TBL] [Abstract][Full Text] [Related]
8. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
[TBL] [Abstract][Full Text] [Related]
9. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
[TBL] [Abstract][Full Text] [Related]
10. miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.
Tan H; He Q; Gong G; Wang Y; Li J; Wang J; Zhu D; Wu X
Int J Oncol; 2016 Jan; 48(1):181-90. PubMed ID: 26575700
[TBL] [Abstract][Full Text] [Related]
11. Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells.
Sehrawat A; Singh SV
Cancer Prev Res (Phila); 2011 Jul; 4(7):1107-17. PubMed ID: 21464039
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.
Wendt MK; Taylor MA; Schiemann BJ; Sossey-Alaoui K; Schiemann WP
Breast Cancer Res; 2014 Mar; 16(2):R24. PubMed ID: 24618085
[TBL] [Abstract][Full Text] [Related]
13. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C
Oncotarget; 2015 Nov; 6(37):40310-26. PubMed ID: 26515598
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA ROR1-AS1 enhances lung adenocarcinoma metastasis and induces epithelial-mesenchymal transition by sponging miR-375.
Xu N; Qiao L; Yin L; Li H
J BUON; 2019; 24(6):2273-2279. PubMed ID: 31983094
[TBL] [Abstract][Full Text] [Related]
15. ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer.
Xu GL; Shen J; Xu YH; Wang WS; Ni CF
Mol Med Rep; 2018 Dec; 18(6):5087-5094. PubMed ID: 30272313
[TBL] [Abstract][Full Text] [Related]
16. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.
Zhang S; Chen L; Cui B; Chuang HY; Yu J; Wang-Rodriguez J; Tang L; Chen G; Basak GW; Kipps TJ
PLoS One; 2012; 7(3):e31127. PubMed ID: 22403610
[TBL] [Abstract][Full Text] [Related]
17. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Satram-Maharaj T; Nyarko JN; Kuski K; Fehr K; Pennington PR; Truitt L; Freywald A; Lukong KE; Anderson DH; Mousseau DD
Cell Signal; 2014 Dec; 26(12):2621-32. PubMed ID: 25152370
[TBL] [Abstract][Full Text] [Related]
18. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
Kong X; Ding X; Li X; Gao S; Yang Q
Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
[TBL] [Abstract][Full Text] [Related]
19. Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells.
Chen TC; Hsu YL; Tsai YC; Chang YW; Kuo PL; Chen YH
J Mol Med (Berl); 2014 Jan; 92(1):53-64. PubMed ID: 24005829
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
Shah P; Gau Y; Sabnis G
Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
